Lupus erythematosus: systemic and cutaneous manifestations
Introduction
Systemic lupus erythematosus (SLE) is a multisystem disease of unknown cause that is characterized by the presence of multiple autoantibodies. Typically, it affects the skin, joints, kidneys, lungs, nervous system, serous membranes, and other systems. The autoantibodies are typically antinuclear antibodies. The clinical course is extremely variable and ranges from life-threatening to mild diseases that never require hospitalization. The disease is predominantly present in women, especially those who are in their 20s and 30s, but it may occur in children and in elderly individuals.
Cutaneous manifestations of SLE are present in 85% of patients during the course of the disease, and musculoskeletal abnormalities are present in approximately 95%.1 Joint and skin manifestations thus occur in nearly all patients with SLE. The disease tends to mimic the manifestations present at onset during subsequent exacerbations.
Musculoskeletal manifestations are the most common feature of SLE.1 Arthritis with objective evidence of pain on motion, tenderness, effusion, or periarticular soft-tissue swelling is present at the time of diagnosis in 88% of patients. Some patients develop arthritis after the diagnosis had been made, such that 89% of patients have arthritis during the disease. Other patients have arthralgia without objective evidence of arthritis, such that 95% of patients have either arthritis or arthralgia.
In some patients, arthralgia or arthritis may precede the onset of multisystem disease by many years. The most common joints involved are the proximal interphalangeal joints (present in 82% of patients). The distribution is nearly always symmetrical. The knees are involved in 76% of patients, followed by the wrists and metacarpophalangeal joints. The ankles, elbows, and shoulders are involved less frequently. Knee effusions can be moderately severe. Aspiration reveals a clear fluid with less than 3000 white blood cells per microliter. Most cells are small lymphocytes, and there is a low protein level. Antinuclear antibodies and lupus erythematosus (LE) cells may be found in the fluid. Serum complement proteins are usually low, reflecting similarly low levels in the serum. Synovial histopathology is nonspecific with diffuse proliferation of lining cells and some perivascular mononuclear cells, enlarged endothelial cells, and thrombi. The arthritis disappears completely within a few days after treatment with corticosteroids for systemic diseases.
If a patient presents with a single swollen or painful joint, one should suspect an alternate diagnosis, such as infectious or crystalline arthritis, for which appropriate diagnostic (eg, joint aspiration) and therapeutic measures should be instituted.
During the course of the disease, patients may develop deformities, but these are not related to joint destruction. Typical swan-neck deformities with ulnar deviation of the fingers develop after 3 to 4 years of disease in approximately 10% of patients who continue to have mild intermittent joint pains. Radiographs of the hands reveal no bony erosion or loss of joint space. Joint subluxation is a result of involvement of the tendons and spasm of the small muscles of the fingers.
Morning stiffness is present in 50% of patients, and typical subcutaneous nodules occur in 10%. Tenosynovitis occurs in approximately 10% of patients, with some patients experiencing rupture of the infrapatellar, deltoid, or Achilles tendons.
Avascular necrosis occurs in approximately 15% of patients after prolonged treatment with high doses of corticosteroids. Avascular necrosis is most common in the femoral heads and presents as anterior groin pain, trochanteric bursal pain, or anterior thigh pain. Radiographs may be negative early after the onset of pain, but magnetic resonance imaging may allow early diagnosis.
Muscle pain is present in approximately 30% of patients, with enzyme abnormalities occurring in approximately 20% of patients before treatment.
Fibromyalgia is common in patients with SLE and must be distinguished from the joint and muscle pain associated with the disease.
Section snippets
Pathophysiology
The pathophysiologic mechanisms of LE-specific skin disease continue to be elucidated.2 It is thought that development of skin disease is related to the same autoimmune abnormalities responsible for the systemic components of LE. Current theories discuss the relationship between genetic susceptibility, autoimmune induction and subsequent expansion, and injury to the immune system.3 Genetic susceptibility is probably related to genes that decrease the threshold for self-reactivity and allow a
General features
Fatigue is present in nearly all patients with SLE during periods of disease activity and can precede the appearance of rashes or joint swelling. Fever is present in approximately 80% of patients at the time of diagnosis and may be of low grade or spiking. Fever in a treated patient with SLE should be considered to be a result of infection until proven otherwise. Weight loss is present in approximately 85% of patients at the time of diagnosis unless the nephrotic syndrome is present.
Cardiovascular manifestations
Clinically
Laboratory findings
One or more hematologic abnormalities are present in nearly all patients with SLE who have active disease. Most commonly, mild to moderate normocytic and normochromic anemia is present. Coombs' test–positive hemolytic anemia occurs in approximately 10% of patients. Mild to moderate leukopenia is present in 17% of patients, and lymphopenia is also usually present during disease activity. Mild thrombocytopenia is present in approximately one third of patients, but less than 100,000 platelets/mm3
Precipitating factors
Sun exposure may induce the onset of SLE and cause exacerbations of the disease. Infections, especially bacterial infections, may occur before the onset of the disease or cause an exacerbation. Infections especially occur before clotting episodes in patients with antiphospholipid antibodies. Surgery or any trauma that induces necrosis of tissue and the release of nuclear antigens may cause an exacerbation of SLE. Pregnancy is associated with the onset of lupus during the last trimester or the
Conventional agents
Systemic glucocorticoids are the standard form of treatment for patients with SLE. Some patients require very low doses of prednisone (≤10 mg) to alleviate manifestations of the disease. Patients with nephritis, central nervous system lupus, or pulmonary hemorrhage may require very high doses, and intravenous therapy is frequently recommended to them. Cyclophosphamide and mycophenolate may be used in conjunction with high doses of glucocorticoids. Author, Naomi Rothfield treats patients with
Treatment: cutaneous manifestations
Comments here will be directed at the treatment of LE-specific skin diseases such as SCLE and CCLE. The second author (RDS) has recently addressed this subject more comprehensively elsewhere.67, 68 Acute cutaneous LE (eg, facial butterfly-shaped erythema reactions) and LE-nonspecific skin lesions (eg, cutaneous vasculitis) are typically seen in the context of active SLE. The systemic immunomodulatory/immunosuppressive treatments required to control the SLE activity will typically in a parallel
Acknowledgment
Dr Sontheimer's contribution to the preparation of this work was supported by the Richard and Adeline Fleischaker Chair in Dermatology Research of the University of Oklahoma Health Sciences Center.
References (109)
- et al.
Systemic lupus erythematous: pathogenesis
Subacute cutaneous lupus erythematosus
Clin Dermatol
(1985)- et al.
Systemic lupus erythematosus with anti-Ro antibodies: clinical, histologic and immunologic findings
J Am Acad Dermatol
(1982) - et al.
Lupus erythematosus and toxic epidermal necrolysis
J Am Acad Dermatol
(1987) Acral subacute cutaneous lupus erythematosus: an unusual variant
J Am Acad Dermatol
(1994)- et al.
Subacute cutaneous lupus erythematosus presenting as erythroderma
J Am Acad Dermatol
(1988) Clinical manifestations of cutaneous lupus erythematosus
Autoimmun Rev
(2005)- et al.
Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases
J Am Acad Dermatol
(1988) - et al.
Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine
J Am Acad Dermatol
(1988) Koebner phenomenon in lupus erythematosus with special consideration of clinical findings
Autoimmun Rev
(2005)
Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation
J Am Acad Dermatol
Panniculitis (Part II). Mostly lobular panniculitis
J Am Acad Dermatol
The application of fluorescent antibody technique to the investigation of lupus erythematosus and various dermatoses
J Invest Dermatol
Newer therapeutic approaches for systemic lupus erythematosus
Rheum Dis Clin North Am
Subacute cutaneous lupus erythematosus: a quarter century's perspective
Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings
Autoimmun Rev
Pimecrolimus 1% cream for cutaneous lupus erythematosus
J Am Acad Dermatol
Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology
Ophthalmology
Annular subacute cutaneous lupus erythematosus responsive to dapsone
J Am Acad Dermatol
Systemic lupus erythematosus: clinical aspects and treatment
Lupus erythematosus
Lupus erythematosus
Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture
Arthritis Rheum
The lexicon of cutaneous lupus erythematosus—a review of personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus
Lupus
Lichenoid tissue reactions: a speculative review of the clinical spectrum of epidermal basal cell damage with special reference to erythema dyschromicum perstans
Arch Dermatol
Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients
Medicine
Annular vesicular lupus erythematosus
Cutis
The anti-Ro antibody system
Int J Dermatol
Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus
Lupus
The interstitial granulomatous drug reaction: a distinctive and pathologic entity
J Cutan Pathol
Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus
Ann Intern Med
Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients
Arthritis Rheum
Subacute cutaneous lupus erythematosus and discoid lupus erythematosus. Comparative histopathologic findings
Arch Dermatol
Chronic cutaneous lupus erythematosus (DLE): a clinical and laboratory investigation of 80 patients
Medicine (Baltimore)
Scarring alopecia in discoid lupus erythematosus
Br J Dermatol
Clinical manifestations of cutaneous lupus erythematosus
Involvement of nails in discoid lupus erythematosus
J Assoc Phys India
Palmar lesions in lupus erythematosus
Arch Dermatol
The “connective tissue diseases”
Phototests in patients with various forms of lupus erythematosus
Int J Dermatol
Immunohistopathology of light-induced skin lesions in lupus erythematosus
Acta Derm Venereol (Stockh)
Standardized ultraviolet-A exposure provokes skin reaction in systemic lupus erythematosus
Lupus
Ultraviolet radiation–induced injury, chemokines, and leukocyte recruitment. An amplification cycle triggering cutaneous lupus erythematosus
Arthritis Rheum
Lupus erythematosus panniculitis (lupus profundus): clinical, histopathological and molecular analysis of nine cases
J Cutan Pathol
Discoid lupus erythematosus lesions developed on lupus erythematosus profundus nodules
Int J Dermatol
Lupus mastitis: a 2-year history of a single localization of lupus erythematosus mimicking breast carcinoma
J Eur Acad Dermotol Venereol
Tumid lupus erythematosus
Am J Dermatopathol
Phototesting in lupus erythematosus tumidus—review of 60 patients
Photochem Photobiol
Cutaneous manifestations associated with antiphospholipid antibodies
Int J Dermatol
Lupus and nonlupus cutaneous manifestations in systemic lupus erythematosus
Aust N Z J Med
Cited by (137)
An Indonesian female with severe cutaneous lupus erythematosus: A case report and literature review
2023, International Journal of Surgery Case ReportsSubacute cutaneous lupus erythematosus: A facultative paraneoplastic dermatosis
2022, Clinics in DermatologySkin manifestations associated with systemic diseases – Part I
2021, Anais Brasileiros de DermatologiaSnapshotDx Quiz: October 2021
2021, Journal of Investigative DermatologyRecognition and Management of Cutaneous Connective Tissue Diseases
2021, Medical Clinics of North AmericaCitation Excerpt :Cutaneous involvement is common in patients with SLE, with more than 80% exhibiting skin findings during their disease course. For 20% to 25% of patients diagnosed with SLE, cutaneous symptoms were the first manifestation of SLE.13,26,27 During the first 3 years following a diagnosis of CLE, 18% of patients are diagnosed with SLE, and 24% of patients diagnosed with CLE have a prior SLE diagnosis.4
- 1
Tel.: + 1 405 271 4662; fax: +1 405 271 7216.